CAMP4 Therapeutics’ $75 Million IPO

Ropes & Gray represented CAMP4 Therapeutics in the transaction, and Paul Hastings represented the underwriters. CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company, announced...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here